RxDoctor Payments Data

Ken Fujimura, MD

Neurology · Arcadia, CANPI 1629426630

Payments from drug & device makers

$8,706in general payments, 2019–2025

Across 414 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$994
  • AbbVie$971
  • Acadia Pharmaceuticals Inc$764
  • Biogen$757
  • AstraZeneca$596
  • Lilly USA, LLC$391
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$8,668100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.64$994
AbbVie(2 entities)62$971
Acadia Pharmaceuticals Inc36$764
Biogen29$757
AstraZeneca(2 entities)26$596
Lilly USA, LLC17$391
Jazz Pharmaceuticals Inc.11$325
Pfizer13$276
Eisai Inc.10$273
Neurelis, Inc.8$193
Amgen(2 entities)9$191
SK Life Science, Inc.8$189
Amneal Pharmaceuticals LLC9$178
Teva Pharmaceuticals USA, Inc.8$174
Lundbeck LLC7$171
EMD Serono, Inc.5$155
Argenx US, Inc.5$115
Johnson & Johnson5$104
Otsuka America Pharmaceutical, Inc.4$96
Neuropace, Inc.4$86
Ipsen Biopharmaceuticals, Inc3$86
Avadel CNS Pharmaceuticals, LLC3$86
Kyowa Kirin, Inc.4$84
Takeda Pharmaceuticals U.S.A., Inc.4$82
Harmony Biosciences LLC2$79
Neurocrine Biosciences, Inc.2$77
Aquestive Therapeutics, Inc.4$73
Corium, LLC3$71
Sumitomo Pharma America, Inc.3$68
Alnylam Pharmaceuticals Inc.3$64
Tanabe Pharma America, Inc.2$62
Bristol Myers Squibb2$54
ANI Pharmaceuticals, Inc.2$53
Merz Pharmaceuticals, LLC1$49
Boston Scientific2$49
C2n Diagnostics, LLC1$49
Xeris Pharmaceuticals, Inc.3$45
Avanir Pharmaceuticals, Inc.2$43
Supernus Pharmaceuticals, Inc.2$43
Azurity Pharmaceuticals, Inc.3$43
Biohaven Pharmaceuticals, Inc.2$36
Genentech USA, Inc.1$35
Immedica Pharma US, Inc.1$34
Scilex Pharmaceuticals Inc.2$33
Biohaven Pharmaceutical Holding Company Ltd.1$30
Greenwich Biosciences, Inc.1$29
Axsome Therapeutics, Inc.1$27
GE HealthCare1$24
Travere Therapeutics, Inc.3$24
Octapharma USA, Inc.1$22
Sobi, Inc1$21
TG Therapeutics, Inc.1$19
Zogenix Inc.1$18
Bioventus LLC1$18
Catalyst Pharmaceuticals, Inc.1$17
CSL Behring1$16
Sanofi1$16
Biomarin Pharmaceutical Inc.1$15
Abbott1$15

How this compares

$8,706 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$218,441
Medicare patients
755
Services billed
2,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Carbidopa-LevodopaCarbidopa/Levodopa61$2,188
Gabapentin83$956
Levetiracetam22$873
Memantine Hcl15$815
Galantamine ErGalantamine Hbr13$401
Amitriptyline Hcl34$320
Donepezil Hcl16$205
Duloxetine Hcl25$164
Folic Acid11$52
Atorvastatin Calcium11$42
Quetiapine Fumarate11$20

Paid to pharmacies, not to this prescriber.

Other neurology in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →